Efficacy and Safety of Oral Valiltramiprosate in APOE4/4 Homozygotes with Early AD: Topline Results from the APOLLOE4 Phase 3 Trial

Abstract

Background: Valiltramiprosate (ALZ‐801) is an oral inhibitor of amyloid oligomer formation. Tramiprosate (active agent in ALZ‐801) had shown promising efficacy signals with favorable safety in ∼1300 APOE4 carriers with AD, with no observed ARIA‐E. This trial evaluated Valiltramiprosate in APOE4/4 homozygotes with Early AD.

The paper